SCHEMBL4091614

SCHEMBL4091614

CC(C)Cc1ccc(-c2cc(N)c(C(N)=O)s2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 7/20 0.62
CYP1A2 P05177 3/20 0.61
CYP2C9 P11712 3/20 0.61
CYP3A4 P08684 2/20 0.61
CYP2C19 P33261 2/20 0.61
CHUK O15111 1/20 0.61
BTK Q06187 1/20 0.60
CDC7 O00311 1/20 0.57
DBF4 Q9UBU7 1/20 0.57
PTPRF P10586 1/20 0.54
PTPN1 P18031 1/20 0.54
PTPRA P18433 1/20 0.54
MAPT P10636 10/20 0.52
ALDH1A1 P00352 6/20 0.52
HDAC6 Q9UBN7 1/20 0.52
KDM4E B2RXH2 8/20 0.49
RAB9A P51151 6/20 0.49
NPC1 O15118 5/20 0.49
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23657912 0.86 MAPT (0.67) IKBKBCYP1A2CYP2C9CYP3A4CYP2C19
SCHEMBL1384269 0.82 PTPRF (0.65) IKBKBPTPRFPTPN1PTPRA
SCHEMBL6611685 0.79 IKBKB (0.72) IKBKBCYP1A2CYP2C9CYP3A4CYP2C19
SCHEMBL6612593 0.79 IKBKB (0.76) IKBKBCYP1A2CYP2C9CYP3A4CYP2C19
SCHEMBL6608113 0.77 IKBKB (0.73) IKBKBCYP1A2CYP2C9CYP3A4CYP2C19
SCHEMBL4097204 0.77 IKBKB (1.00) IKBKBCYP1A2CYP2C9CYP3A4CYP2C19
SCHEMBL4091841 0.76 IKBKB (1.00) IKBKBCYP1A2CYP2C9CYP3A4CYP2C19
SCHEMBL4097325 0.76 IKBKB (1.00) IKBKBCYP1A2CYP2C9CYP3A4CYP2C19
SCHEMBL1847243 0.76 IKBKB (1.00) IKBKBCYP1A2CYP2C9CYP3A4CYP2C19
SCHEMBL5551103 0.76 PTPN1 (0.78) IKBKBPTPRFPTPN1PTPRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166639-B2 NF-κB inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-01-23 US claimed
US-20040192943-A1 Nf-kappab inhibitors SMITHKLINE BEECHAM CORPORATION 2004-09-30 US claimed
US-20090181962-A1 Substituted thiophene compounds ASTRAZENECA AB, A SWEDEN CORPORATION 2009-07-16 US disclosed
US-7358376-B2 Substituted Thiophene compounds ASTRAZENECA AB (SE) 2008-04-15 US disclosed
CN-1243747-C Heteroaromatic carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 ASTRAZENECA AB (SE) 2006-03-01 CN disclosed
EP-1261600-B1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 ASTRAZENECA AB (SE) 2004-05-06 EP disclosed
EP-1261600-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 AstraZeneca AB (SE) 2002-12-04 EP disclosed
US-20020107252-A1 Novel Compounds ASTRAZENECA AB (SE) 2002-08-08 US disclosed
WO-2001058890-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 ASTRAZENECA AB (SE) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181962-A1 Substituted thiophene compounds ABCG2, SULT1E1, TPMT IKBKB 3065/4885CYP1A2 4/4885CYP2C9 7/4885
US-20020107252-A1 Novel Compounds UGT1A1, CYP1B1, CYP1A1 IKBKB 2413/4885CYP1A2 4/4885CYP2C9 25/4885
US-20040192943-A1 Nf-kappab inhibitors NFKBIA, IKBKB, IKBKG IKBKB 2/4885CYP1A2 3982/4885CYP2C9 4698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.